In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.
At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business.
The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping.
Researchers identified a new type 2 diabetes-associated site involving the ZRANB3 gene, which may have a role in regulating pancreatic beta cells.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
The deal makes Greenville, South Carolina-based Premier the only US lab to offer the genetic risk analysis assay from Spain's Patia.
In Genome Biology this week: study of 'dark' genome regions, algorithm to determine DNA methylation variation, and more.
In Nature this week: Integrative Human Microbiome Project researchers investigate host-microbiome relationship in health and disease, and more.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.